503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
2026 Head-to-Head Fee & Dose-Escalation Teardown · DOI 10.5281/zenodo.24139315

Sequence (WW Clinic) vs. Losing Weight RX (2026 Cost Audit): $99/mo Subscription + $49 Setup + Retail Rx

Audited 52-Week Cost Verdict

In our 2026 52-week pharmacoeconomic audit (DOI 10.5281/zenodo.24139315), Sequence (WW Clinic) totals $14,196 over 13 four-week cycles ($113.44/mg at 2.4 mg semaglutide maintenance) due to subscription covers prior-authorization paperwork only; uninsured or denied patients still face $990–$1,060 retail medication bills. Losing Weight RX locks Semaglutide at $49/mo ($588/52 weeks, $5.10/mg) and Tirzepatide at $99/mo ($1,188/52 weeks) with $0 membership fees.

Audit DimensionSequence (WW Clinic)Losing Weight RX (Verified Lock)
Billing Structure$99/mo Subscription + $49 Setup + Retail Rx$49/mo Semaglutide · $99/mo Tirzepatide All-Inclusive
Mandatory Monthly MembershipIncluded in $14,196 total above$0.00 / month
High-Dose Escalation Surcharge (2.4mg / 15mg)Applies on tiered/retail plans$0.00 (Same Flat Price All Doses)
Effective $/mg (2.4 mg/wk Semaglutide)$113.44/mg$5.10 / mg
Minimum Contract Commitment3 Months1 Month (Cancel Anytime)
52-Week Cumulative Semaglutide Spend$14,196$637 (13 Four-Week Cycles @ $49)

Key Consumer Finding: Sequence (WW Clinic)

Subscription covers prior-authorization paperwork only; uninsured or denied patients still face $990–$1,060 retail medication bills.

Source: US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026) · Zenodo DOI 10.5281/zenodo.24139315.

Switch Without Restarting at Starter Doses

Keep your current prescribed titration tier at $49/mo Semaglutide or $99/mo Tirzepatide—with $0 monthly platform dues.

Switch & Lock $49/mo →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Sequence (WW Clinic) vs. Losing Weight RX (2026 Cost Audit): $99/mo Subscription + $49... is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519
  2. Kasagga, A., Rebellow, D., Hashmi, T., Husami, M. Y., Lama, P., Arul Selvan, K., & Nakasagga, K. (2025). Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials. Cureus, 17(8), e90335. https://doi.org/10.7759/cureus.90335
  3. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  4. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know
  6. Wen, J., Syed, B., Nadora, D., How-Volkman, C., Bernstein, E., Truong, A., Akhtar, M., Razick, A., Puglisi, J., & Frezza, E. (2025). Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinology, diabetes & metabolism, 8(3), e70045. https://doi.org/10.1002/edm2.70045